S. Park

J. Ahn, M. Ahn, Keunchil Park, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer

Joon-Oh Park, Hyo Song Kim, S. Park, 2009, BMC Cancer.

Direct analysis of aberrant glycosylation on haptoglobin in patients with gastric cancer

S. J. Lee, Joon-Oh Park, S. Park, 2016, Oncotarget.

Outcomes of Third-Line Docetaxel-Based Chemotherapy in Advanced Gastric Cancer Who Failed Previous Oxaliplatin-Based and Irinotecan-Based Chemotherapies

S. Park, I. Hwang, Byeong-Bae Park, 2012, Cancer research and treatment : official journal of Korean Cancer Association.

Gastrointestinal malignancies harbor actionable MET exon 14 deletions

Joon-Oh Park, H. Kim, S. Ou, 2015, Oncotarget.

Are There Any Ethnic Differences in Molecular Predictors of Erlotinib Efficacy in Advanced Non-Small Cell Lung Cancer?

P. Jänne, C. Ki, J. Ahn, 2008, Clinical Cancer Research.

Predictors of Erlotinib Efficacy in Advanced Non-Small Cell Lung Cancer ?

C. Ki, J. Ahn, M. Ahn, 2008 .

Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target.

Joon-Oh Park, C. Ki, S. Park, 2011, Oncology reports.

ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy

S. Park, G. Kwon, B. Jeong, 2012, BMC Cancer.

Predictive value of the ERCC1 expression for treatment response and survival in advanced gastric cancer patients receiving cisplatin-based first-line chemotherapy.

Joon-Oh Park, S. Park, Kyoung-Mee Kim, 2010, Cancer research and treatment : official journal of Korean Cancer Association.

Glycomic profiling of targeted serum haptoglobin for gastric cancer using nano LC/MS and LC/MS/MS.

S. Park, Seung-Yeol Park, H. An, 2016, Molecular bioSystems.

The impact of pathologic differentiation (well/poorly) and the degree of Ki-67 index in patients with metastatic WHO grade 3 GEP-NECs

Joon-Oh Park, S. Park, Jeeyun Lee, 2017, Oncotarget.

A phase II study of oxaliplatin in combination with doxorubicin as first-line systemic chemotherapy in patients with inoperable hepatocellular carcinoma

Joon-Oh Park, S. Park, K. Koh, 2009, Cancer Chemotherapy and Pharmacology.

Nomogram to Predict Treatment Outcome of Fluoropyrimidine/Platinum-Based Chemotherapy in Metastatic Esophageal Squamous Cell Carcinoma

Y. Shim, S. Park, Y. Im, 2013, Cancer research and treatment : official journal of Korean Cancer Association.

Natural history of metastatic biliary tract cancer (BTC) patients with good performance status (PS) who were treated with only best supportive care (BSC).

Joon-Oh Park, S. Park, I. Hwang, 2015, Japanese journal of clinical oncology.

A Retrospective Study of First-Line Therapy Involving Immune Checkpoint Inhibitors in Patients With Poor Risk Metastatic Renal Cell Carcinoma

S. Park, B. K. Park, G. Kwon, 2022, Frontiers in Oncology.

Genomic Profiling of Metastatic Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients in the Personalized-Medicine Era

Su Jin Lee, S. J. Lee, Joon-Oh Park, 2016, Journal of Cancer.

Effects of single nucleotide polymorphisms on treatment outcomes and toxicity in patients treated with sunitinib.

Joon-Oh Park, S. Park, Jeeyun Lee, 2013, Anticancer research.

A prospective phase-II trial of biweekly docetaxel plus androgen deprivation therapy in patients with previously-untreated metastatic castration-naïve prostate cancer

S. Park, H. Jeon, S. Seo, 2021, BMC Cancer.

Docetaxel rechallenge in metastatic castration-resistant prostate cancer: A retrospective, single-center study

S. Park, H. Jeon, S. Jeon, 2020, Investigative and clinical urology.

Circulating Tumor Cells are Predictive of Poor Response to Chemotherapy in Metastatic gastric cancer

Su Jin Lee, S. J. Lee, Joon-Oh Park, 2015, International Journal of Biological Markers.

CD151 Overexpression is Associated with Poor Prognosis in Patients with pT3 Gastric Cancer

Joon-Oh Park, S. Park, Kyoung-Mee Kim, 2014, Annals of Surgical Oncology.

Inhibitory effects of Synurus excelsus and Weigela subsessilis on aldose reductase and HPLC-UV analysis of scopolin, scopoletin, and quercetin

S. Park, Sanghyun Lee, S. Jacinto, 2018, Journal of Applied Biological Chemistry.

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.

J. Burke, T. Powles, T. Choueiri, 2021, The New England journal of medicine.

In reply to Mauer et al. “Statistical methodology is crucial in prognostic factor-analysis of health-related quality of life”

S. Park, 2008, Quality of Life Research.

Heparin-Induced Thrombocytopenia (HIT) in Patients with Acute Coronary Syndrome: Incidence and Clinical Feature, Retrospective Study

S. Park, E. Cho, D. Shin, 2005 .

Comparative effectiveness of palliative chemotherapy versus neoadjuvant chemotherapy followed by radical cystectomy versus cystectomy followed by adjuvant chemotherapy versus cystectomy for regional node‐positive bladder cancer: A retrospective analysis: KCSG GU 17‐03

S. Park, J. Byun, H. Kim, 2019, Cancer medicine.

Clinical Experience of Male Primary Choriocarcinoma at the Samsung Medical Center

S. Park, Y. Ji, 2020, Cancer research and treatment : official journal of Korean Cancer Association.

High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features.

S. Park, R. Cristescu, Kyoung-Mee Kim, 2020, Pathology, research and practice.

Systematic Evaluation of Gastric Tumor Cell Index and Two-Drug Combination Therapy via 3-Dimensional High-Throughput Drug Screening

Jason K. Sa, Dong Woo Lee, Joon-Oh Park, 2019, Front. Oncol..

Development of mesenchymal subtype gene signature for clinical application in gastric cancer

S. Park, R. Cristescu, Kyoung-Mee Kim, 2017, Oncotarget.

Chemotherapy beyond second-line in advanced gastric cancer.

S. Park, S. Kim, 2015, World journal of gastroenterology.

Inhibitory activity of methanol extracts from different colored flowers on aldose reductase and HPLC-UV analysis of quercetin

S. Park, Sanghyun Lee, Sanghyun Lee, 2018, Horticulture, Environment, and Biotechnology.

Docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment: a phase II clinical trial

S. Park, E. Cho, D. Shin, 2005, BMC Cancer.

Multiple Opportunistic Infections Related to Hypercortisolemia due to Adrenocortical Carcinoma: A Case Report

S. Park, C. Kang, J. Hong, 2020, Infection & chemotherapy.

VIKTORY trial: Report on AZD1775/paclitaxel in TP53 mutation (+) GC, selumetinib/paclitaxel in ras aberrant GC, AZD5363/paclitaxel in PIK3CA mt and biomarker negative, savolitinib/docetaxel in met (+), and vistusertib/paclitaxel in RICTOR(+) GC.

Joon-Oh Park, S. Park, E. Harrington, 2017 .

Changes in Corneal Topography after 23-Gauge Transconjunctival Vitrectomy

S. Park, J. Yum, Jonghyun Lee, 2012 .

LAG3 in Solid Tumors as a Potential Novel Immunotherapy Target

Su Jin Lee, Joon-Oh Park, S. Park, 2019, Journal of immunotherapy.

MerTK inhibition by RXDX-106 in MerTK activated gastric cancer cell lines

Joon-Oh Park, S. Park, Kyoung-Mee Kim, 2017, Oncotarget.

The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors

Joon-Oh Park, S. Park, Kyoung-Mee Kim, 2021, Journal of Cancer Research and Clinical Oncology.

High delta-like ligand 4 expression correlates with a poor clinical outcome in gastric cancer

S. Park, W. You, Kyoung-Mee Kim, 2019, Journal of Cancer.

Simvastatin plus capecitabine-cisplatin versus placebo plus capecitabine-cisplatin in patients with previously untreated advanced gastric cancer: a double-blind randomised phase 3 study.

Joon-Oh Park, S. Park, I. Hwang, 2014, European journal of cancer.

Changes in quality of life during palliative chemotherapy for solid cancer

S. Park, E. Cho, D. Shin, 2005, Supportive Care in Cancer.

Probiotic suppression of the H. pylori-induced responses by conjugated linoleic acids in a gastric epithelial cell line.

Jung Mogg Kim, J. S. Kim, H. Jung, 2012, Prostaglandins, leukotrienes, and essential fatty acids.

Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.

J. Witjes, M. Galsky, M. Milowsky, 2021, The New England journal of medicine.

Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma.

Craig B. Davis, T. Powles, S. Park, 2020, The New England journal of medicine.

First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients

Joon-Oh Park, D. Nam, Keunchil Park, 2020, Therapeutic advances in medical oncology.

Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma.

C. Tournigand, T. Powles, S. Park, 2022, European urology.

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase III KEYNOTE-564 study.

T. Powles, T. Choueiri, S. Park, 2021 .

Homologous Recombination Deficiency as a Novel Therapeutic Target in Various Solid Tumors

Joon-Oh Park, S. Park, Kyoung-Mee Kim, 2021 .

Development of Novel Patient-Derived Preclinical Models from Malignant Effusions in Patients with Tyrosine Kinase Inhibitor–Resistant Clear Cell Renal Cell Carcinoma1

O. Rath, S. Park, W. Park, 2017, Translational oncology.

Enfortumab vedotin-related pneumonitis is more common than expected and could lead to acute respiratory failure.

S. Park, Young Saing Kim, B. Keam, 2022, European journal of cancer.

Subsequent Systemic Therapy following Platinum and Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma

S. Park, H. Sung, B. Jeong, 2022, Biomedicines.

Palliative chemotherapy for non-transitional cell carcinomas of the urothelial tract

Joon-Oh Park, S. Park, W. Kim, 2009, Medical oncology.

Clinical scoring system for the prediction of survival of patients with advanced gastric cancer

Jong Soo Choi, D. Chang, S. Park, 2020, ESMO Open.

Second-line chemotherapy for patients with oesophagogastric adenocarcinoma.

S. Park, 2014, The Lancet. Oncology.

A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma.

S. Park, Young Saing Kim, I. Hwang, 2016, Clinical genitourinary cancer.

Phase II study of epirubicin, cisplatin, and capecitabine for advanced biliary tract adenocarcinoma

S. Park, E. Cho, D. Shin, 2006, Cancer.

Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis.

T. Powles, S. Park, C. Sternberg, 2020 .

Phase I study of intraperitoneal irinotecan in patients with gastric adenocarcinoma with peritoneal seeding

Joon-Oh Park, S. Park, D. Yim, 2010, Cancer Chemotherapy and Pharmacology.

A pilot study of cisplatin, irinotecan, leucovorin and 5-fluorouracil (PILF) combination chemotherapy for advanced gastric cancer.

S. Park, E. Cho, D. Shin, 2006, Cancer research and treatment : official journal of Korean Cancer Association.

The efficacy of frontline platinum-based combination chemotherapy in advanced adenocarcinoma of the ampulla of Vater

S. Choi, D. Choi, J. K. Lee, 2010, Medical oncology.

A randomized trial of anemia correction with two different hemoglobin targets in the first-line chemotherapy of advanced gastric cancer

S. Park, E. Cho, D. Shin, 2008, Cancer Chemotherapy and Pharmacology.

Predictive Value of the ERCC 1 Expression for Treatment Response and Survival in Advanced Gastric Cancer Patients Receiving Cisplatin-based First-line Chemotherapy

Joon-Oh Park, S. Park, Kyoung-Mee Kim, 2010 .

Clinical characteristics and prognostic factors for primary appendiceal carcinoma

S. Park, J. Byun, Jin-Hyoung Kang, 2010, Asia-Pacific journal of clinical oncology.

Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.

T. H. Klotz, S. Culine, J. Hainsworth, 2022, The Lancet. Oncology.

Screening for somatic mutations in esophageal squamous cell carcinoma using OncoMap 4.0.

L. Macconaill, S. Park, P. Hummelen, 2012, Journal of Clinical Oncology.

Tumor Necrosis Factor-α Enhances DMSO-Induced Differentiation of HL-60 Cells through Activation of ERK/MAPK Pathway.

S. Park, Jinny Park, D. Shin, 2007 .

Vascular Complications in Patients with Essential Thrombocythemia

S. Park, E. Cho, D. Shin, 2006 .

A Randomized Phase II Study of Leucovorin/5-Fluorouracil with or without Oxaliplatin (LV5FU2 vs. FOLFOX) for Curatively-Resected, Node-Positive Esophageal Squamous Cell Carcinoma

M. Ahn, Keunchil Park, Y. Shim, 2016, Cancer research and treatment : official journal of Korean Cancer Association.

Prospective pilot study of consolidation chemotherapy with docetaxel and cisplatin after concurrent chemoradiotherapy for advanced head and neck cancer.

S. Park, Jinny Park, E. Cho, 2008, International journal of radiation oncology, biology, physics.

Treatment Outcome and Relevance of Palliative Chemotherapy in Urachal Cancer

S. Park, G. Kwon, H. Lim, 2014, Chemotherapy.

Changeable Conditional Survival Rates and Associated Prognosticators in Patients with Metastatic Renal Cell Carcinoma Receiving First Line Targeted Therapy

S. Park, J. Y. Park, C. Kwak, 2018, The Journal of urology.

A comparison of FOLFIRI (Folinic Acid, Fluorouracil and Irinotecan) Plus Bevacizumab and FLOLFIRI Plus Aflibercept as Second-Line Treatment for Metastatic Colorectal Cancer

Joon-Oh Park, S. Park, Jeeyun Lee, 2020 .

Neoadjuvant Nivolumab Plus Gemcitabine/Cisplatin Chemotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder

S. Park, G. Kwon, H. Sung, 2022, Cancer research and treatment.

A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer

S. Park, Y. Bang, Keun-Wook Lee, 2019, Gastric Cancer.

ERDAFITINIB in locally advanced or metastatic urothelial carcinoma (mUC): Long-term outcomes in BLC2001.

R. Huddart, M. Fleming, B. Mellado, 2020 .

Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer

Joon-Oh Park, S. Park, Kyoung-Mee Kim, 2020, Translational cancer research.

Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer.

Joon-Oh Park, S. Park, J. Cho, 2018 .

Outcomes of metastatic gastric cancer in young adult patients treated with first-line combination chemotherapy

S. Park, S. Kim, Kyoungha Kim, 2015 .

Phase III study of pembrolizumab (pembro) plus olaparib versus enzalutamide (enza) or abiraterone acetate (abi) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who progressed on chemotherapy: KEYLYNK-010.

S. Park, E. Antonarakis, Jeri Kim, 2020 .

Salvage Chemotherapy with Paclitaxel, Ifosfamide, and Cisplatin (TIP) in Relapsed or Cisplatin-Refractory Germ Cell Tumors

Joon-Oh Park, S. Park, Jeeyun Lee, 2011, Oncology Research and Treatment.

First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt).

R. Huddart, B. Mellado, S. Park, 2018 .

Five-gene signature for the prediction of response to immune checkpoint inhibitors in patients with gastric and urothelial carcinomas.

S. Park, Kyoung-Mee Kim, G. Kwon, 2022, Pathology, research and practice.

Neoadjuvant chemotherapy with gemcitabine and cisplatin followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of bladder

S. Park, G. Kwon, H. Sung, 2022, Investigative and clinical urology.

Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma

Joon-Oh Park, Keunchil Park, Jeeyun Lee, 2004, Cancer Chemotherapy and Pharmacology.

Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.

R. Huddart, M. Fleming, B. Mellado, 2019, The New England journal of medicine.

A Case of Urinary Tract Infection Caused by the Emerging Uropathogen Actinotignum schaalii

C. Ki, S. Park, N. Lee, 2019, Laboratory Medicine Online.

Changes in Higher Order Aberration After Implantable Contact Lens Implantation

S. Park, J. Yum, S. Choi, 2010 .

Stabilization of epidermal growth factor on thermal and proteolytic degradation by conjugating with low molecular weight chitosan

S. Park, T. Son, M. K. Kim, 2006 .

Prognostic model in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitors after platinum failure.

S. Park, Kwonoh Park, B. Keam, 2022, Current problems in cancer.

Programmed Death Ligand 1 Expression as a Prognostic Marker in Patients with Advanced Biliary Tract Cancer

Joon-Oh Park, S. Park, K. Jang, 2021, Oncology.

Single-cell RNA sequencing reveals the tumor microenvironment and facilitates strategic choices to circumvent treatment failure in a chemorefractory bladder cancer patient

D. Nam, S. Park, W. Park, 2020, Genome Medicine.

PD-L1 expression as a prognostic marker in patients with advanced biliary tract cancer.

Joon-Oh Park, S. Park, Jeeyun Lee, 2020 .

Adjuvant Chemotherapy with or without Concurrent Radiotherapy for Patients with Stage IB Gastric Cancer: a Subgroup Analysis of the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Phase III Trial

Su Jin Lee, Joon-Oh Park, S. Park, 2018, Journal of gastric cancer.

Randomized double-blinded, placebo-controlled phase II trial of simvastatin and gemcitabine in advanced pancreatic cancer patients

S. Choi, Joon-Oh Park, S. Park, 2013, Cancer Chemotherapy and Pharmacology.

Comprehensive pharmacogenomic characterization of gastric cancer

Joon-Oh Park, D. Nam, S. Park, 2020, Genome Medicine.

Comprehensive pharmacogenomic characterization of gastric cancer

Joon-Oh Park, D. Nam, S. Park, 2020, Genome Medicine.

Tumor genomic profiling guides metastatic gastric cancer patients to targeted treatment: The VIKTORY Umbrella Trial.

Joon-Oh Park, S. Park, Young Saing Kim, 2019, Cancer discovery.

Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial.

S. Park, Y. Bang, D. Hodgson, 2017, The Lancet. Oncology.

Patient-derived cell models as preclinical tools for genome-directed targeted therapy

Joon-Oh Park, O. Rath, S. Park, 2015, Oncotarget.

The Impact of Concomitant Genomic Alterations on Treatment Outcome for Trastuzumab Therapy in HER2-Positive Gastric Cancer

Kyoung-Mee Kim, S. Park, Kyoung-Mee Kim, 2015, Scientific Reports.

Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series

Su Jin Lee, Hyo Song Kim, S. Park, 2015, BMC Cancer.

Prognostic Model to Predict Survival Outcome for Curatively Resected Liposarcoma: A Multi-Institutional Experience

Young Han Lee, Hyo Song Kim, S. Park, 2016, Journal of Cancer.

Malignant Gastrointestinal Stromal Tumor in a Patient with Neurofibromatosis type 1

J. Oh, S. Park, D. Shin, 2007, The Korean journal of internal medicine.

Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer

Joon-Oh Park, A. Bass, S. Park, 2018, Nature Medicine.

NanoString expression profiling identifies candidate biomarkers of RAD001 response in metastatic gastric cancer

Bin Tean Teh, Kyoung-Mee Kim, B. Teh, 2016, ESMO Open.

Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial.

J. Lacy, S. Park, Y. Bang, 2020, The Lancet. Oncology.

Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy

Joon-Oh Park, S. Park, Kyoung-Mee Kim, 2017, Oncotarget.

Pilot study of sirolimus in patients with PIK3CA mutant/amplified refractory solid cancer

Joon-Oh Park, S. Park, K. S. Jung, 2017, Molecular and clinical oncology.

Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial

Joon-Oh Park, S. Park, Young Saing Kim, 2019 .

The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors

Joon-Oh Park, Keunchil Park, S. Park, 2016, OncoTarget.

Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study.

C. Drake, S. Park, E. Antonarakis, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of KRAS Mutations on Clinical Outcomes in Pancreatic Cancer Patients Treated with First-line Gemcitabine-Based Chemotherapy

Joon-Oh Park, S. Park, Yoon-La Choi, 2011, Molecular Cancer Therapeutics.

c‐MET Overexpression in Colorectal Cancer: A Poor Prognostic Factor for Survival

Su Jin Lee, Joon-Oh Park, S. Park, 2018, Clinical colorectal cancer.

An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach.

Joon-Oh Park, Keunchil Park, Jeeyun Lee, 2005, International journal of radiation oncology, biology, physics.

Oxaliplatin and UFT Combination Chemotherapy in Patients With Metastatic Colorectal Cancer

Joon-Oh Park, W. Lee, Keunchil Park, 2002, American journal of clinical oncology.

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Fernando Maciel Barbosa, Raymond J. McDermott, J. Burke, 2022, The Lancet. Oncology.

Prospective Feasibility Study for Using Cell-Free Circulating Tumor DNA–Guided Therapy in Refractory Metastatic Solid Cancers: An Interim Analysis

Joon-Oh Park, Keunchil Park, S. Park, 2017, JCO Precision Oncology.

Prognostic impact of the pretreatment aspartate transaminase/alanine transaminase ratio in patients treated with first‐line systemic tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma

S. Park, Minyong Kang, H. Sung, 2018, International journal of urology : official journal of the Japanese Urological Association.

The Impact of Primary Tumor Sidedness on the Effect of Regorafenib in Refractory Metastatic Colorectal Cancer

Su Jin Lee, Joon-Oh Park, S. Park, 2019, Journal of Cancer.

Clinical and molecular distinctions in patients with refractory colon cancer who benefit from regorafenib treatment

Joon-Oh Park, Y. Cho, S. Park, 2020, Therapeutic advances in medical oncology.

Safety and Efficacy of Adjuvant Chemoradiation Therapy With Capecitabine After Resection of Pancreatic Ductal Adenocarcinoma: A Retrospective Review

S. Choi, D. Choi, J. K. Lee, 2012, American Journal of Clinical Oncology.

Korean Treatment Guidelines for Metastatic Prostate Cancer Developed by the Korean Association for Clinical Oncology

S. Park, J. Jo, Kwonoh Park, 2017 .

A Novel Proteomics-Based Clinical Diagnostics Technology Identifies Heterogeneity in Activated Signaling Pathways in Gastric Cancers

Joon-Oh Park, S. Park, Kyoung-Mee Kim, 2013, PloS one.

Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.

Myung Ah Lee, Joon-Oh Park, S. Park, 2012, The Lancet. Oncology.

Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer

Joon-Oh Park, S. Park, I. Kozarewa, 2021, Clinical Cancer Research.

Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors

Joon-Oh Park, S. Park, Kyoung-Mee Kim, 2021, Therapeutic advances in medical oncology.

Antitumor Effect of AZD4547 in a Fibroblast Growth Factor Receptor 2–Amplified Gastric Cancer Patient–Derived Cell Model

S. Park, Kyoung-Mee Kim, Jeeyun Lee, 2017, Translational oncology.

Irinotecan plus carboplatin in patients with extensive-disease small-cell lung cancer

S. Park, Young Saing Kim, Jinny Park, 2011, Medical oncology.

A nCounter CNV Assay to Detect HER2 Amplification: A Correlation Study with Immunohistochemistry and In Situ Hybridization in Advanced Gastric Cancer

Sin-Ho Jung, S. Park, Kyoung-Mee Kim, 2016, Molecular Diagnosis & Therapy.

Prognostic Impact of Sarcopenia in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Byul A. Jee, S. Park, Minyong Kang, 2021, Cancers.

Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study

Young Suk Park, Joong Bae Ahn, Jae Ho Byun, 2009, Cancer Chemotherapy and Pharmacology.

2020 Korean guidelines for the management of metastatic prostate cancer

Young Seok Kim, S. Park, Kwonoh Park, 2020, The Korean journal of internal medicine.

Korean guidelines for the management of metastatic prostate cancer

Young Seok Kim, S. Park, Kwonoh Park, 2021 .

The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs

Joon-Oh Park, S. Park, Kyoung-Mee Kim, 2016, Journal of Cancer.

Tissue recommendations for precision cancer therapy using next generation sequencing: a comprehensive single cancer center’s experiences

Joon-Oh Park, M. Ahn, Keunchil Park, 2017, Oncotarget.

BAYOU: A phase II, randomized, multicenter, double-blind, study of durvalumab (D) in combination with olaparib (O) for the first-line treatment of platinum-ineligible patients with unresectable, stage IV urothelial carcinoma (UC).

D. Bajorin, S. Park, J. Rosenberg, 2022, Journal of Clinical Oncology.

Small Molecule Therapeutics Pazopanib , a Novel Multitargeted Kinase Inhibitor , Shows Potent In Vitro Antitumor Activity in Gastric Cancer Cell Lines with FGFR 2 Ampli fi cation

Su Jin Lee, Joon-Oh Park, S. Park, 2014 .

A randomized double-blind placebo-controlled study of low-dose intravenous Lorazepam to reduce procedural pain during bone marrow aspiration and biopsy.

S. Park, E. Cho, D. Shin, 2008, Pain medicine.

HER2‐positive gastric cancer with concomitant MET and/or EGFR overexpression: A distinct subset of patients for dual inhibition therapy

Sung Kim, Joon-Oh Park, S. Park, 2015, International journal of cancer.

Retrospective analysis of extra-gastrointestinal stromal tumors.

S. Park, D. Shin, I. Hwang, 2015, World journal of gastroenterology.

A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: a multicentre, multinational study.

Joon-Oh Park, D. Doval, S. Thongprasert, 2012, European journal of cancer.

Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan

Su Jin Lee, Joon-Oh Park, H. Kim, 2015, BMC Cancer.

Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy

Joon-Oh Park, D. Chang, Y. Cho, 2010, Cancer Chemotherapy and Pharmacology.

Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab

Joon-Oh Park, Y. Cho, S. Yun, 2014, Investigational New Drugs.

Fat Loss in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors

S. Park, Soohyun Hwang, G. Kwon, 2023, International journal of molecular sciences.

Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16)

Dong Sook Kim, S. Park, Keun-Wook Lee, 2021, Therapeutic advances in medical oncology.

S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial.

S. Park, Y. Bang, Yoon-Koo Kang, 2020, The Lancet. Oncology.

Tumor Mutational Burden Determined by Panel Sequencing Predicts Survival After Immunotherapy in Patients With Advanced Gastric Cancer

S. Park, Kyoung-Mee Kim, Jeeyun Lee, 2020, Frontiers in Oncology.

Early Experiences with Nivolumab in Patients with Metastatic Renal Cell Carcinoma and Failed Target Therapy

S. Park, G. Kwon, Minyong Kang, 2019, The Korean Journal of Urological Oncology.

Novel Predictive Models of Early Death Less Than 1 Year in Patients With Metastatic Renal Cell Carcinoma After Treatment With First-line Tyrosine Kinase Inhibitors.

S. Park, Minyong Kang, H. Sung, 2019, Clinical genitourinary cancer.

The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma

Su Jin Lee, Joon-Oh Park, S. Park, 2019, Journal of Cancer.

The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma

Su Jin Lee, Joon-Oh Park, S. Park, 2019, Journal of Cancer.

Safety and efficacy of trastuzumab administered as a 30-min infusion in patients with HER2-positive advanced gastric cancer

S. Park, Jeeyun Lee, H. Lim, 2018, Cancer Chemotherapy and Pharmacology.

Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma

R. Motzer, T. Powles, T. Choueiri, 2018, British Journal of Cancer.

Management of Fibroblast Growth Factor Inhibitor Treatment-emergent Adverse Events of Interest in Patients with Locally Advanced or Metastatic Urothelial Carcinoma.

R. Huddart, B. Mellado, S. Park, 2023, European urology open science.

Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU)

D. Bajorin, S. Park, J. Rosenberg, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase II Trial of Tipifarnib for Patients with Previously Treated, Metastatic Urothelial Carcinoma Harboring HRAS Mutations

S. Park, A. Gualberto, G. Kwon, 2020, Clinical Cancer Research.

Synergistic Effects of Combination Therapy with AKT and mTOR Inhibitors on Bladder Cancer Cells

Su Jin Lee, S. Park, H. Sung, 2020, International journal of molecular sciences.

Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.

S. Park, A. Navarro, M. Schuler, 2019, The Lancet. Oncology.

The Outcomes of Hypertransfusion in Major ABO Incompatible Allogeneic Stem Cell Transplantation

Joon-Oh Park, Keunchil Park, S. Park, 2004, Journal of Korean medical science.

PD10-01 DISEASE-FREE SURVIVAL WITH LONGER FOLLOW-UP FROM THE CHECKMATE 274 TRIAL OF ADJUVANT NIVOLUMAB IN PATIENTS AFTER SURGERY FOR HIGH-RISK MUSCLE-INVASIVE UROTHELIAL CARCINOMA

J. Witjes, M. Galsky, D. Bajorin, 2022, Journal of Urology.

Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up results from the JAVELIN Bladder 100 trial.

T. Powles, S. Park, C. Sternberg, 2022, Journal of Clinical Oncology.

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.

T. Powles, M. Galsky, S. Park, 2020, The Lancet. Oncology.

Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors: An updated analysis of EV-201 Cohort 2.

M. Harrison, S. Park, E. Heath, 2021, Journal of Clinical Oncology.

Erdafitinib (ERDA; JNJ-42756493), a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRa): Phase 2 continuous versus intermittent dosing.

R. Huddart, B. Mellado, S. Park, 2018 .

Excision repair cross‐complementation group 1 (ERCC1) expression in advanced urothelial carcinoma patients receiving cisplatin‐based chemotherapy

Jeeyun Lee, S. Park, I. Do, 2010, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

Thalidomide for Treating Metastatic Hepatocellular Carcinoma: A Pilot Study

S. Park, E. Cho, D. Shin, 2006, The Korean journal of internal medicine.

Phase II Study of Dovitinib in Patients with Castration-Resistant Prostate Cancer (KCSG-GU11-05)

S. Park, H. Song, Dong-Yeop Shin, 2018, Cancer research and treatment : official journal of Korean Cancer Association.

Correlation between MEK signature and Ras gene alteration in advanced gastric cancer

S. Park, J. Dry, D. Hodgson, 2017, Oncotarget.

Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Results from 30-month follow-up of KEYNOTE-564.

T. Powles, T. Choueiri, S. Park, 2022, Journal of Clinical Oncology.

Radium‐223 in Asian patients with castration‐resistant prostate cancer with symptomatic bone metastases: A single‐arm phase 3 study

Xingdang Liu, F. Zhou, Rui Li, 2020, Asia-Pacific journal of clinical oncology.

Neutralizing antibody to FGFR2 can act as a selective biomarker and potential therapeutic agent for gastric cancer with FGFR2 amplification.

Joon-Oh Park, S. Park, Kyoung-Mee Kim, 2019, American journal of translational research.

Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion

S. Park, W. Park, T. Ahn, 2017, Oncotarget.

Value of FGFR2 expression for advanced gastric cancer patients receiving pazopanib plus CapeOX (capecitabine and oxaliplatin)

Su Jin Lee, Joon-Oh Park, S. Park, 2016, Journal of Cancer Research and Clinical Oncology.

Pazopanib, a Novel Multitargeted Kinase Inhibitor, Shows Potent In Vitro Antitumor Activity in Gastric Cancer Cell Lines with FGFR2 Amplification

Su Jin Lee, Joon-Oh Park, S. Park, 2012, Molecular Cancer Therapeutics.

Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer

Joon-Oh Park, Keunchil Park, Jeeyun Lee, 2005, Cancer Chemotherapy and Pharmacology.

Use of Gefitinib in EGFR-Amplified Refractory Solid Tumors: An Open-Label, Single-Arm, Single-Center Prospective Pilot Study

Joon-Oh Park, D. Nam, S. Park, 2020, Targeted Oncology.

Rogaratinib treatment of patients with advanced urothelial carcinomas prescreened for tumor FGFR mRNA expression.

S. Park, M. Schuler, H. Richly, 2018 .

Exome Sequencing Identifies Early Gastric Carcinoma as an Early Stage of Advanced Gastric Cancer

Joon-Oh Park, S. Park, Seonwoo Kim, 2013, PloS one.

Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone.

Joon-Oh Park, S. Park, D. Shin, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Detection of Fusion Genes Using a Targeted RNA Sequencing Panel in Gastrointestinal and Rare Cancers

Su Jin Lee, Joon-Oh Park, S. Park, 2020, Journal of oncology.

Antitumor activity of sorafenib plus CDK4/6 inhibitor in pancreatic patient derived cell with KRAS mutation

Joon-Oh Park, S. Park, Kyung Kim, 2018, Journal of Cancer.

Clinical Significance of IGFBP-3 Methylation in Patients with Early Stage Gastric Cancer

Joon-Oh Park, S. Park, Kyoung-Mee Kim, 2015, Translational oncology.

Phase I dose-escalating study of docetaxel in combination with 5-day continuous infusion of 5-fluorouracil in patients with advanced gastric cancer

S. Park, E. Cho, D. Shin, 2005, BMC Cancer.

Role of Adjuvant Chemotherapy in Advanced Stage Upper Urinary Tract Urothelial Carcinoma after Radical Nephroureterectomy: Competing Risk Analysis after Propensity Score-Matching

S. Park, Kyunga Kim, Minyong Kang, 2019, Journal of Cancer.

Nanostring-Based Multigene Assay to Predict Recurrence for Gastric Cancer Patients after Surgery

Insuk Sohn, Young Suk Park, Kyoung-Mee Kim, 2014, PloS one.

MCT4 as a potential therapeutic target for metastatic gastric cancer with peritoneal carcinomatosis

Jin Hyun Cho, Joon-Oh Park, S. Park, 2016, Oncotarget.

Successful use of pazopanib for treatment of refractory metastatic hemangiopericytoma

Su Jin Lee, S. Park, Yoon-La Choi, 2014, Clinical Sarcoma Research.

Antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients (pts) with advanced HER2+ (IHC3+) gastric carcinoma (GC).

J. Lacy, S. Park, Y. Bang, 2019, Journal of Clinical Oncology.

KEYNOTE-564: A phase 3, randomized, double blind, trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma.

T. Powles, T. Choueiri, S. Park, 2018 .

Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer

Joon-Oh Park, S. Park, K. Jang, 2015, Translational Oncology.

MerTK is a novel therapeutic target in gastric cancer

Joon-Oh Park, S. Park, Jeonghee Cho, 2015, Oncotarget.

Oxaliplatin, folinic acid and 5-fluorouracil (FOLFOX-4) combination chemotherapy as second-line treatment in advanced colorectal cancer patients with irinotecan failure: a Korean single-center experience.

J. Oh, S. Park, E. Cho, 2005, Japanese journal of clinical oncology.

Salvage chemotherapy with irinotecan and cisplatin in patients with metastatic gastric cancer failing both 5-fluorouracil and taxanes

S. Park, D. Shin, J. H. Lee, 2005, Anti-cancer drugs.

Molecular biomarkers for advanced renal cell carcinoma: implications for prognosis and therapy.

Hyo Song Kim, S. Park, I. Hwang, 2010, Urologic oncology.

Identification of FGFR3-TACC3 gene fusion in metastatic gastric cancer

S. Park, Kyoung-Mee Kim, Jeeyun Lee, 2017 .

Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability

S. Park, Kyoung-Mee Kim, Jeeyun Lee, 2017, Oncotarget.

Triptolide as a novel agent in pancreatic cancer: the validation using patient derived pancreatic tumor cell line

Joon-Oh Park, S. Park, Kyung Kim, 2018, BMC Cancer.

A Phase II Study of Epirubicin, Cisplatin and Capecitabine Combination Chemotherapy in Patients with Metastatic or Advanced Gastric Cancer

S. Park, E. Cho, D. Shin, 2005, Oncology.

The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer

Joon-Oh Park, D. Chang, Y. Cho, 2010, Medical oncology.

Clinical Features of Waldenstrom Macroglobulinemia in Korea

S. Park, E. Cho, D. Shin, 2004, The Korean journal of internal medicine.

Tuberculosis in hematopoletk stem cell transplant recipients in Korea

Joon-Oh Park, Keunchil Park, Jeeyun Lee, 2004, International journal of hematology.

Phase II trial of weekly docetaxel and gemcitabine for previously untreated, advanced non-small cell lung cancer.

S. Park, Junshik Hong, Jinny Park, 2008, Lung cancer.

Quality of life of patients with soft tissue sarcoma treated with doxorubicin in the ANNOUNCE phase III clinical trial

S. Park, B. V. Van Tine, A. Krarup-Hansen, 2022, Rare tumors.

A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma

S. Park, H. Lim, Se-Hoon Lee, 2016, BMC Urology.

Opioid rotation versus combination for cancer patients with chronic uncontrolled pain: a randomized study

S. Park, Young Saing Kim, Hyun-Jun Kim, 2015, BMC Palliative Care.

Genomic Sequencing for Bladder Urothelial Carcinoma and Its Clinical Implications for Immunotherapy

S. Park, G. Kwon, B. Jeong, 2021, Cancer research and treatment.

Metastatic lymph node in gastric cancer; Is it a real distant metastasis?

S. Park, C. Park, Jeeyun Lee, 2010, BMC Cancer.

NTRK gene amplification in patients with metastatic cancer

Joon-Oh Park, Keunchil Park, S. Park, 2017 .

SOURCE: A Registry-Based Prediction Model for Overall Survival in Patients with Metastatic Oesophageal or Gastric Cancer

A. Zwinderman, J. Ajani, M. Sprangers, 2019, Cancers.

Olaratumab and doxorubicin for the treatment of metastatic soft tissue sarcoma: a retrospective case series

Su Jin Lee, S. Park, J. Hur, 2019, Precision and Future Medicine.

Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients

Joon-Oh Park, H. Kim, W. Lee, 2015, Oncotarget.

Pemetrexed versus Gefitinib versus Erlotinib in Previously Treated Patients with Non-Small Cell Lung Cancer

S. Park, Junshik Hong, Jinny Park, 2010 .

Gefitinib (ZD1839) Monotherapy as a Salvage Regimen for Previously Treated Advanced Non-Small Cell Lung Cancer

Joon-Oh Park, Keunchil Park, S. Park, 2004, Clinical Cancer Research.

BEZ235 (PIK3/mTOR inhibitor) Overcomes Pazopanib Resistance in Patient-Derived Refractory Soft Tissue Sarcoma Cells

Su Jin Lee, O. Rath, S. Park, 2016, Translational oncology.

Docetaxel Plus Cisplatin as Second-Line Therapy in Metastatic or Recurrent Advanced Gastric Cancer Progressing on 5-Fluorouracil-Based Regimen

Joon-Oh Park, Keunchil Park, S. Park, 2004, American journal of clinical oncology.

Effect of baseline sarcopenia on adjuvant treatment for D2 dissected gastric cancer: Analysis of the ARTIST phase III trial.

S. Park, Kyoung-Mee Kim, D. Lim, 2020, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

The impact of microsatellite instability status and sidedness of the primary tumor on the effect of bevacizumab-containing chemotherapy in patients with metastatic colorectal cancer

Joon-Oh Park, S. Park, Jeeyun Lee, 2018, Journal of Cancer.

The Impact of Microsatellite Instability Status and Sidedness of the Primary Tumor on the Effect of Cetuximab-Containing Chemotherapy in Patients with Metastatic Colorectal Cancer

Joon-Oh Park, S. Park, Su-Jin Lee, 2017, Journal of Cancer.

A Prognostic Model to Predict Clinical Outcomes with First-Line Gemcitabine-Based Chemotherapy in Advanced Pancreatic Cancer

S. Choi, D. Choi, J. K. Lee, 2011, Oncology.

Treatment of dexamethasone-induced hiccup in chemotherapy patients by methylprednisolone rotation.

Ha Yeon Lee, E. Bruera, S. Park, 2013, The oncologist.

TreatmentofDexamethasone-InducedHiccup inChemotherapy PatientsbyMethylprednisoloneRotation

S. Park, J. Kang, Y. Choi, 2013 .

Chemoradiotherapy followed by surgery in rectal cancer: improved local control using a moderately high pelvic radiation dose.

J. Oh, S. Park, D. Shin, 2008, Japanese journal of clinical oncology.

P059 Efficacy and safety of cabazitaxel plus prednisolone chemotherapy for metastatic castration-resistant prostatic carcinoma: Data on Korean patients obtained by the cabazitaxel compassionate use program

S. Park, H. Lim, Se-Hoon Lee, 2014 .

Effectiveness and safety of cabazitaxel plus prednisolone chemotherapy for metastatic castration-resistant prostatic carcinoma: data on Korean patients obtained by the cabazitaxel compassionate-use program

S. Park, S. Koh, H. Lim, 2014, Cancer Chemotherapy and Pharmacology.

Estimating Survival Probabilities of Advanced Gastric Cancer Patients in the Second-Line Setting: The Gastric Life Nomogram

S. Park, L. Antonuzzo, R. Miceli, 2018, Oncology.

Erratum: Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab (Investigational New Drugs (2014) 32 (535-541) DOI: 10.1007/s10637-014-0065-x)

Joon-Oh Park, Y. Cho, S. Yun, 2014 .

Metastatic urachal carcinoma of the ovary

S. Park, C. Choi, D. Bae, 2011, The journal of obstetrics and gynaecology research.

Changes in the Mean Corpuscular Volume after Capecitabine Treatment Are Associated with Clinical Response and Survival in Patients with Advanced Gastric Cancer

Joon-Oh Park, S. Park, Jeeyun Lee, 2014, Cancer research and treatment : official journal of Korean Cancer Association.

Anti-Inflammatory Effect of Artemisia argyi on Ethanol-Induced Gastric Ulcer: Analytical, In Vitro and In Vivo Studies for the Identification of Action Mechanism and Active Compounds

S. Park, K. Kang, M. Shin, 2021, Plants.

Which Patients Benefit from Preoperative Chemoradiotherapy for Intermediate Staged Rectal Cancer?

Joon-Oh Park, Y. Cho, S. Yun, 2011, Oncology Research and Treatment.

Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma

S. Park, Lilin Zhang, Jiyan Liu, 2020, Cancer science.

High-Throughput Genotyping in Metastatic Esophageal Squamous Cell Carcinoma Identifies Phosphoinositide-3-Kinase and BRAF Mutations

Kyoung-Mee Kim, Paul van Hummelen, So Young Kang, 2012, PloS one.

Prognostic Impact of Microsatellite Instability in Asian Gastric Cancer Patients Enrolled in the ARTIST Trial

S. Park, R. Miceli, Kyoung-Mee Kim, 2019, Oncology.

Squamous Cell Carcinoma of the Pancreas: A Case Report

S. Park, S. Kim, J. Shin, 2018 .

Paclitaxel versus docetaxel for advanced gastric cancer: a randomized phase II trial in combination with infusional 5-fluorouracil

S. Park, E. Cho, D. Shin, 2006, Anti-cancer drugs.

A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer

S. Park, Yoon-Koo Kang, Yeul-Hong Kim, 2017, Cancer Chemotherapy and Pharmacology.

Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16)

Dong Sook Kim, S. Park, Keun-Wook Lee, 2022, Gastric Cancer.

Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma

S. Park, E. Cho, D. Shin, 2006, BMC Cancer.

ARTIST 2: Interim results of a phase III trial involving adjuvant chemotherapy and/or chemoradiotherapy after D2-gastrectomy in stage II/III gastric cancer (GC).

S. Park, I. Hwang, Kyoung-Mee Kim, 2019, Journal of Clinical Oncology.

Margetuximab (M) plus pembrolizumab (P) in ERBB2-amplified PD-L1+ gastroesophageal adenocarcinoma (GEA) post trastuzumab (T).

J. Lacy, S. Park, Y. Bang, 2018 .

Atezolizumab in Patients with Pretreated Urothelial Cancer: a Korean Single-Center, Retrospective Study

Su Jin Lee, S. Park, G. Kwon, 2019, Cancer research and treatment : official journal of Korean Cancer Association.

Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in MET-Amplified Gastric Cancer

J. Barrett, S. Park, Kyoung-Mee Kim, 2020, JCO precision oncology.

Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer.

T. Powles, S. Park, C. Sternberg, 2022, Future oncology.

Pemetrexed Monotherapy as Salvage Treatment in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy: A Phase II Single-arm Prospective Trial

Joon-Oh Park, S. Park, Jeeyun Lee, 2018, Journal of Cancer.

Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma

R. Motzer, T. Powles, T. Choueiri, 2018, British Journal of Cancer.

Phase I Trial of Anti‐MET Monoclonal Antibody in MET‐Overexpressed Refractory Cancer

Joon-Oh Park, M. Ahn, S. Park, 2018, Clinical colorectal cancer.

Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis

S. Park, N. Tsuchiya, Jae-Lyun Lee, 2022, International Journal of Clinical Oncology.

Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma

Su Jin Lee, S. Park, Young Saing Kim, 2018, BMC Urology.

Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial.

T. Powles, S. Park, C. Sternberg, 2023, European urology.

Role of adjuvant therapy after R0 resection for patients with distal cholangiocarcinoma

Joon-Oh Park, S. Park, Young Saing Kim, 2016, Cancer Chemotherapy and Pharmacology.

Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis

S. Park, Tae Won Kim, H. Kang, 2013, Cancer Chemotherapy and Pharmacology.

Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series

S. Park, K. Yoo, S. Rha, 2015, BMC Cancer.

Definitive chemoradiation therapy with capecitabine in locally advanced pancreatic cancer

S. Choi, D. Choi, J. K. Lee, 2009, Anti-cancer drugs.

Mitomycin C plus S-1 as second-line therapy in patients with advanced gastric cancer: a noncomparative phase II study

S. Park, Young Saing Kim, Junshik Hong, 2008, Anti-cancer drugs.

Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study

Su Jin Lee, Yeon-Hee Park, S. Park, 2015, BMC Cancer.

Intrinsic resistance to sunitinib in patients with metastatic renal cell carcinoma

S. Park, I. Hwang, S. Lim, 2017, Asia-Pacific journal of clinical oncology.

Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study

S. Park, D. Shin, Y. Bang, 2012, Acta oncologica.

Phase 1a study results investigating the safety and preliminary efficacy of ABL001 (NOV1501), a bispecific antibody targeting VEGF and DLL4 in metastatic gastrointestinal (GI) cancer.

Joon-Oh Park, S. Park, W. You, 2019, Journal of Clinical Oncology.

Pazopanib for the Treatment of Non-clear Cell Renal Cell Carcinoma: A Single-Arm, Open-Label, Multicenter, Phase II Study

S. Park, K. S. Jung, H. Lim, 2017, Cancer research and treatment : official journal of Korean Cancer Association.

EV-201 Cohort 2: Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors.

M. Harrison, S. Park, E. Heath, 2021 .

First results from the phase 3 CheckMate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma (MIUC).

J. Witjes, M. Galsky, D. Bajorin, 2021 .

Fierce-21: Phase II study of vofatmab (B-701), a selective inhibitor of FGFR3, as salvage therapy in metastatic urothelial carcinoma (mUC).

B. Mellado, S. Park, A. Necchi, 2019, Journal of Clinical Oncology.

Rogaratinib in patients with advanced urothelial carcinomas prescreened for tumor FGFR mRNA expression and effects of mutations in the FGFR signaling pathway.

S. Park, A. Navarro, M. Schuler, 2018 .

Chemotherapy vs supportive care alone for relapsed gastric, gastroesophageal junction, and oesophageal adenocarcinoma: a meta-analysis of patient-level data

S. Park, A. Marshall, J. Dunn, 2016, British Journal of Cancer.

The efficacy of the frontline platinum-based combination chemotherapy in malignant peritoneal mesothelioma.

Joon-Oh Park, S. Park, Jeeyun Lee, 2010, Japanese Journal of Clinical Oncology.

The Efﬁcacy of the Frontline Platinum-based Combination Chemotherapy in Malignant Peritoneal Mesothelioma

Joon-Oh Park, S. Park, Jeeyun Lee, 2010 .

Comparison of the 7th and the 8th AJCC Staging System for Non-metastatic D2-Resected Lymph Node–Positive Gastric Cancer Treated with Different Adjuvant Protocols

Su Jin Lee, Joon-Oh Park, S. Park, 2018, Cancer research and treatment : official journal of Korean Cancer Association.

First-Line Chemotherapy with Irinotecan plus Capecitabine for Advanced Colorectal Cancer

J. Oh, S. Park, E. Cho, 2004, Oncology.

TPK1 as a predictive marker for the anti-tumour effects of simvastatin in gastric cancer.

Joon-Oh Park, S. Park, Kyoung-Mee Kim, 2020, Pathology, research and practice.

To Excavate Biomarkers Predictive of the Response for Capecitabine plus RAD001 through Nanostring-Based Multigene Assay in Advanced Gastric Cancer Patients

Joon-Oh Park, I. Sohn, S. Park, 2016, Journal of Cancer.

Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up

T. Powles, S. Park, C. Sternberg, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer

Su Jin Lee, Joon-Oh Park, Sin-Ho Jung, 2015, Oncotarget.

Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma.

M. Ahn, Jeeyun Lee, S. Park, 2015, World journal of gastroenterology.

Adjuvant pembrolizumab (pembro) for renal cell carcinoma (RCC) across UCLA Integrated Staging System (UISS) risk groups and disease stage: Subgroup analyses from the KEYNOTE-564 study.

T. Choueiri, S. Park, P. Tomczak, 2023, Journal of Clinical Oncology.

Necessity of adjuvant concurrent chemo-radiotherapy in D2-resected LN-positive gastric cancer.

Su Jin Lee, Joon-Oh Park, S. Park, 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

The Correlation Between Serum Chemokines and Clinical Outcome in Patients with Advanced Biliary Tract Cancer

Su Jin Lee, Joon-Oh Park, S. Park, 2018, Translational oncology.

The efficacy of low-dose transdermal fentanyl in opioid-naïve cancer patients with moderate-to-severe pain

Keunchil Park, S. Park, H. Lee, 2014, The Korean journal of internal medicine.

Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study

Su Jin Lee, Yeon-Hee Park, S. Park, 2015, BMC Cancer.

High-Throughput Sequencing and Copy Number Variation Detection Using Formalin Fixed Embedded Tissue in Metastatic Gastric Cancer

S. Park, Duk-Hwan Kim, Kyoung-Mee Kim, 2014, PloS one.

Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial

Joon-Oh Park, S. Park, Kyoung-Mee Kim, 2019, Translational oncology.

Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy

Joon-Oh Park, S. Park, Jeeyun Lee, 2017, BMC Cancer.

Is There a Role for Adjuvant Therapy in R0 Resected Gallbladder Cancer?: A Propensity Score-Matched Analysis

Joon-Oh Park, S. Park, Young Saing Kim, 2016, Cancer research and treatment : official journal of Korean Cancer Association.

Clinical Application of Targeted Deep Sequencing in Solid-Cancer Patients and Utility for Biomarker-Selected Clinical Trials.

Joon-Oh Park, P. Park, H. Kim, 2017, The oncologist.

A nCounter CNV Assay to Detect HER2 Amplification: A Correlation Study with Immunohistochemistry and In Situ Hybridization in Advanced Gastric Cancer

Sin-Ho Jung, S. Park, Kyoung-Mee Kim, 2016, Molecular Diagnosis & Therapy.

The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis

Joon-Oh Park, H. Kim, J. Ahn, 2015, Oncotarget.

2318 Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer

S. Park, Joobae Park, K. Yoo, 2015 .

Expression of activated signal transducer and activator of transcription 3 predicts poor clinical outcome in gastric adenocarcinoma

Joon-Oh Park, S. Park, C. Park, 2009, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

A phase II trial of concurrent chemoradiation therapy followed by consolidation chemotherapy with oral etoposide and cisplatin for locally advanced inoperable non-small cell lung cancers.

Joon-Oh Park, Keunchil Park, S. Park, 2003, Lung Cancer.

Triptolide as a novel agent in pancreatic cancer: the validation using patient derived pancreatic tumor cell line

Joon-Oh Park, S. Park, Kyung Kim, 2018, BMC Cancer.

Prospective phase II trial of regional hyperthermia and whole liver irradiation for numerous chemorefractory liver metastases from colorectal cancer

Joon-Oh Park, S. Park, Jeeyun Lee, 2016, Radiation Oncology Journal.

Depletion of l‐ascorbic acid alternating with its supplementation in the treatment of patients with acute myeloid leukemia or myelodysplastic syndromes

S. Park, B. Kimler, Y. Min, 2009, European journal of haematology.

Malignant gastrointestinal stromal tumor in a patient with neurofibromatosis type 1.

J. Oh, S. Park, D. Shin, 2007, The Korean Journal of Internal Medicine.

PD-L1 and immune infiltrates are differentially expressed in distinct subgroups of gastric cancer

J. Barrett, S. Park, D. Hodgson, 2018, Oncoimmunology.

Randomized phase II trial of two different schedules of docetaxel plus cisplatin as first‐line therapy in advanced nonsmall cell lung cancer

S. Park, E. Cho, S. Jeong, 2007, Cancer.

IOL tilt and decentration.

S. Park, N. Maeda, S. Choi, 2010, Ophthalmology.

A Randomized Phase II Study of Leucovorin/5-Fluorouracil with or without Oxaliplatin (LV5FU2 vs. FOLFOX) for Curatively-Resected, Node-Positive Esophageal Squamous Cell Carcinoma

M. Ahn, Keunchil Park, Y. Shim, 2016, Cancer research and treatment : official journal of Korean Cancer Association.

Outcomes based on prior VEGFR TKI and PD-1 checkpoint inhibitor therapy in METEOR, a randomized phase 3 trial of cabozantinib (C) vs everolimus (E) in advanced renal cell carcinoma (RCC).

R. Motzer, T. Powles, T. Choueiri, 2016 .

Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Analysis of clinical and genomic subgroups from the JAVELIN Bladder 100 trial.

Craig B. Davis, T. Powles, K. Ching, 2021 .

Avelumab first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): Analysis of time to end of next-line therapy in JAVELIN Bladder 100.

T. Powles, S. Park, J. Bellmunt, 2021 .

Atezolizumab (atezo) monotherapy versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma (mUC): Clinical outcomes by PD-L1 status in cisplatin (cis)-ineligible pts from the phase III IMvigor130 study.

M. Galsky, S. Park, E. Kikuchi, 2021 .

Abstract CT042: Atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem in patients (pts) with previously untreated locally advanced or metastatic urothelial carcinoma (mUC): Updated overall survival (OS) from the randomized phase III study IMvigor130

M. Galsky, S. Park, P. O’Donnell, 2021, Clinical Trials.

Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt).

R. Huddart, S. Park, J. Ku, 2023, Journal of Clinical Oncology.

PD09-10 AVELUMAB FIRST-LINE (1L) MAINTENANCE FOR ADVANCED UROTHELIAL CARCINOMA (UC): LONG-TERM OUTCOMES FROM JAVELIN BLADDER 100 IN SUBGROUPS DEFINED BY RESPONSE TO 1L CHEMOTHERAPY

T. Powles, S. Park, C. Sternberg, 2023, Journal of Urology.

Final overall survival (OS) analysis of atezolizumab (atezo) monotherapy vs chemotherapy (chemo) in untreated locally advanced or metastatic urothelial carcinoma (mUC) from the Phase 3 IMvigor130 study.

S. Park, E. Kikuchi, I. Davis, 2023, Journal of Clinical Oncology.

Atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem for first-line (1L) treatment (tx) of locally advanced or metastatic urothelial carcinoma (mUC): Final OS from the randomized Phase 3 IMvigor130 study.

S. Park, P. O’Donnell, E. Kikuchi, 2023, Journal of Clinical Oncology.

The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma

Su Jin Lee, Joon-Oh Park, S. Park, 2019, Journal of Cancer.

Phase 1b/2 study of margetuximab (M) plus pembrolizumab (P) in advanced HER2+ gastroesophageal junction (GEJ) or gastric (G) adenocarcinoma (GEA).

S. Park, Y. Bang, Yoon-Koo Kang, 2018 .

Bridging genomics and phenomics of gastric carcinoma

Joon-Oh Park, S. Park, Kyoung-Mee Kim, 2019, International journal of cancer.

Clinical Outcomes and the Role of Adjuvant Concurrent Chemoradiation Therapy in D2-resected LN-positive Young Patients (≤45 Years) With Gastric Cancer

Joon-Oh Park, S. Park, D. Lim, 2019, AntiCancer Research.

First-in-human phase I trial of anti-hepatocyte growth factor (HGF) antibody (YYB101) in refractory solid tumor patients.

Joon-Oh Park, D. Nam, S. Park, 2018 .

Outcomes of Radiotherapy for Mesenchymal and Non-Mesenchymal Subtypes of Gastric Cancer

S. Park, Kyoung-Mee Kim, D. Lim, 2020, Cancers.

Preliminary activity of tipifarnib in tumors of the head and neck, salivary gland and urothelial tract with HRAS mutations.

S. Park, A. Ho, A. Gualberto, 2020 .

Prognostic Factors of Survival with Aflibercept and FOLFIRI (fluorouracil, leucovorin, irinotecan) as Second-line Therapy for Patients with Metastatic Colorectal Cancer

Joon-Oh Park, S. Park, Jeeyun Lee, 2021, Journal of Cancer.

The Influence of Metastatic Lymph Node Ratio on the Treatment Outcomes in the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Trial: A Phase III Trial

Su Jin Lee, Joon-Oh Park, S. Park, 2016, Journal of gastric cancer.

Reply to F.C.M. Cananzi et al.

S. Park, W. Kang, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Joon-Oh Park, I. Sohn, Sin-Ho Jung, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract CT040: Updated overall survival (OS) analysis of atezolizumab (atezo) monotherapy vs chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (mUC) in IMvigor130

M. Galsky, S. Park, M. Santis, 2021, Clinical Trials.

Efficacy and safety of lenvatinib plus pembrolizumab vs sunitinib in the East Asian subset of patients with advanced renal cell carcinoma from the CLEAR trial

T. Choueiri, S. Park, T. Buchler, 2023, International Journal of Cancer.

Circulating Tumor Cells are Predictive of Poor Response to Chemotherapy in Metastatic gastric cancer

Su Jin Lee, Joon-Oh Park, S. Park, 2015, The International journal of biological markers.

The efficacy of the frontline platinum-based combination chemotherapy in malignant peritoneal mesothelioma.

Joon-Oh Park, S. Park, Jeeyun Lee, 2010, Japanese journal of clinical oncology.

Neutrophilic Myositis without Cutaneous Involvement as the First Manifestation of Acute Myeloid Leukemia

S. Park, S. Bang, J. Ahn, 2005, The Korean journal of internal medicine.

Multicenter phase III trial of adjuvant chemoradiotherapy in stomach tumors 2 (ARTIST 2).

Su Jin Lee, Joon-Oh Park, S. Park, 2015 .

Treatment of Hemodialyzed Patients with Sunitinib in Renal Cell Carcinoma

Jin Hyun Cho, Joon-Oh Park, S. Park, 2010, Chemotherapy.

Impact of Radiotherapy on Kidney Function among Patients Who Received Adjuvant Treatment for Gastric Cancer: Logistic and Linear Regression Analyses

S. Park, D. Lim, Jeeyun Lee, 2020, Cancers.

Probiotic suppression of the H. pylori-induced responses by conjugated linoleic acids in a gastric epithelial cell line.

Jung Mogg Kim, H. Jung, S. Park, 2012, Prostaglandins, leukotrienes, and essential fatty acids.

Clinical Significance of Preoperative Hematological Parameters in Patients with D2-Resected, Node-Positive Stomach Cancer

S. Park, D. Lim, Jeeyun Lee, 2022, Biomedicines.

Factors Influencing Clinicians' Choice of Adjuvant S-1 versus Capecitabine plus Oxaliplatin after Curative Gastrectomy in Patients with Gastric Cancer

S. Park, Young Saing Kim, I. Hwang, 2016, Journal of Cancer.

Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy

Joon-Oh Park, S. Park, Jeeyun Lee, 2017, BMC Cancer.

HER2‐positive gastric cancer with concomitant MET and/or EGFR overexpression: A distinct subset of patients for dual inhibition therapy

Joon-Oh Park, S. Park, C. Park, 2015, International journal of cancer.

Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial

R. Greil, S. Park, E. Antonarakis, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-line pembrolizumab (pembro) with or without lenvatinib (lenva) in patients with advanced urothelial carcinoma (LEAP-011): A phase 3, randomized, double-blind study.

S. Park, A. Balar, M. Gumus, 2022, Journal of Clinical Oncology.

A Rare Cause of Acute Scrotal Pain: Spontaneous Thrombosis of Testicular Vein

S. Park, J. Cho, 2018 .

Adjuvant chemoradiation with 5-fluorouracil/leucovorin versus S-1 in gastric cancer patients following D2 lymph node dissection surgery: a feasibility study.

Su Jin Lee, Joon-Oh Park, S. Park, 2014, Anticancer research.

Vascular Complications in Patients with Essential Thrombocythemia

S. Park, E. Cho, D. Shin, 2006 .

Phase I trial and pharmacokinetic study of Tanibirumab, a fully human monoclonal antibody to the vascular endothelial growth factor receptor 2 in patients with refractory solid tumors.

Joon-Oh Park, M. Ahn, S. Park, 2015 .

Early concurrent chemoradiotherapy with prolonged oral etoposide and cisplatin for limited-stage small-cell lung cancer.

Joon-Oh Park, Keunchil Park, S. Park, 2003, Japanese journal of clinical oncology.